NZV930

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Colorectal Cancer Microsatellite Stable (MSS)Metastatic Castration Resistant Prostate Cancer (mCRPC)Non-small Cell Lung Cancer (NSCLC)Ovarian CancerPancreatic Ductal Adenocarcinoma (PDAC)Renal Cell Carcinoma (RCC)Solid TumorsTriple Negative Breast Cancer (TNBC)

Early Phase 1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

TerminatedNCT04237649

Novartis PharmaceuticalsSolid Tumors

Start: 2020-02-20End: 2023-09-15Updated: 2025-05-18

Phase 1

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

TerminatedNCT03549000

Novartis PharmaceuticalsColorectal Cancer Microsatellite Stable (MSS), Metastatic Castration Resistant Prostate Cancer (mCRPC), Non-small Cell Lung Cancer (NSCLC) +4

Start: 2018-07-18End: 2022-10-17Updated: 2024-12-13

Related Papers

Abstract B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies

Molecular Cancer Therapeutics2023-12-01

Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies

Cancer Research2022-06-156 citations